加拿大通过管制前体化学品和设备,加强禁毒法律,以遏制芬太尼和甲基安非他明的生产。 Canada strengthens drug laws to curb fentanyl and meth production by regulating precursor chemicals and equipment.

加拿大更新了其《受管制药物和物质法》,以打击非法芬太尼和甲基安非他明生产。 Canada has updated its Controlled Drugs and Substances Act to crack down on illegal fentanyl and methamphetamine production. 新规则要求有执照的公司报告涉及麻黄碱、伪麻黄碱、P2P和NPP等前体化学品的可疑交易,并采取步骤防止转用。 New rules require licensed companies to report suspicious transactions involving precursor chemicals like ephedrine, pseudoephedrine, P2P, and NPP, and to take steps to prevent diversion. 这些化学品在消毒剂和其他产品中的销售受到限制,获得药物制造设备,如药片压片的机会也受到限制。 Sales of these chemicals in decongestants and other products are restricted, and access to drug-making equipment like pill presses is limited. 对于用于非法药物制造的某些部件,现在必须进行进口登记。 Import registration is now mandatory for certain components used in illicit drug manufacturing. 这些变化旨在扰乱有组织犯罪、减少过量死亡和防止非法出口,是在加拿大卫生部和加拿大皇家骑警的投入下制定的。 The changes, aimed at disrupting organized crime, reducing overdose deaths, and preventing illegal exports, were developed with input from Health Canada and the RCMP.